Threshold Pharmaceuticals Announces Its Two Phase 3 Studies

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Threshold Pharmaceuticals Announces Its Two Phase 3 Studies Evaluating Evofosfamide Did Not Meet Primary Endpoints

SOUTH SAN FRANCISCO, CA--(Marketwired - Dec 7, 2015) - Threshold Pharmaceuticals, Inc. ( NASDAQ : THLD ) today announced the outcomes of two Phase 3 cancer studies (MAESTRO and TH-CR-406/SARC021) of evofosfamide (previously known as TH-302), an investigational hypoxia-activated prodrug, which is being evaluated for first-line treatment of advanced pancreatic adenocarcinoma and advanced soft tissue sarcoma, in combination with chemotherapy. The Phase 3 studies are being conducted under Threshold's collaboration with Merck KGaA, Darmstadt, Germany.

In the Phase 3 MAESTRO study, patients with previously untreated, locally advanced unresectable or metastatic pancreatic adenocarcinoma treated with evofosfamide in combination with gemcitabine did not demonstrate a statistically significant improvement in overall survival (OS) compared with gemcitabine plus placebo (hazard ratio [HR]: 0.84; 95% confidence interval [CI]: 0.71 - 1.01; p=0.0589).

In the Phase 3 TH-CR-406/SARC021 study being conducted in collaboration with the Sarcoma Alliance for Research through Collaboration (SARC), patients with locally advanced unresectable or metastatic soft tissue sarcoma treated with evofosfamide in combination with doxorubicin did not demonstrate a statistically significant improvement in OS compared with doxorubicin alone (HR: 1.06; 95% CI: 0.88 - 1.29).

Patient safety was monitored in MAESTRO and TH-CR-406/SARC021 by independent data monitoring committees throughout the conduct of each study. No new clinically significant safety findings were observed.

Detailed results from both studies will be submitted for presentation at upcoming international scientific meetings and for publication in peer-reviewed journals. Threshold will not be pursing further development of evofosfamide in soft tissue sarcoma and pancreatic cancer. 

"We are surprised and disappointed that these studies did not show that evofosfamide could extend the lives of patients with these two difficult-to-treat diseases," said Barry Selick, Ph.D., Chief Executive Officer at Threshold. "Threshold has been pursuing evofosfamide for over ten years in collaboration with world-class scientists and investigators throughout the world. While we believe there remains substantial data to support the role of hypoxia in cancer treatment resistance, we are deeply frustrated with our inability in these trials to impact that in a meaningful way. I would like to thank all of the patients and their families, and the physicians, nurses, and support staff who participated in these studies."

Conference Call and Webcast At 8:30 a.m. Eastern Time on Monday December 7, 2015, Threshold's management will host a conference call and a simultaneous webcast. The webcast can be accessed on the company's website in the Investors/Webcasts section http://investor.thresholdpharm.com/events.cfm . Alternatively, please call 1- (888) 767-9745 (U.S) or (440) 996-5547 (international). The conference ID number is 99761325. The webcast will be archived on Threshold's website for at least 30 days.

About TH-CR-406/SARC021 TH-CR-406/SARC021 is a randomized, open-label, global, multicenter Phase 3 study, that was designed to assess the efficacy and safety of evofosfamide (300 mg/m 2 ) in combination with doxorubicin (75 mg/m 2 ) compared with doxorubicin alone, in patients with locally advanced unresectable or metastatic soft tissue sarcoma previously untreated with chemotherapy. A total of 640 patients were randomized in the study. The primary endpoint of the study is OS. Secondary endpoints include progression-free survival (PFS), response rate, safety and pharmacokinetics.

About MAESTRO MAESTRO ( M et A static or unr ES ectable pancrea T ic adenoca R cin O ma) is a randomized, placebo-controlled, international, multicenter, double-blind Phase 3 study, that was designed to assess the efficacy and safety of evofosfamide (340 mg/m 2 ) in combination with gemcitabine (1000 mg/m 2 ), compared with gemcitabine and placebo, in patients with previously untreated, locally advanced, unresectable or metastatic pancreatic adenocarcinoma. A total of 693 patients were randomized in the study. The primary endpoint of the study is OS. Secondary endpoints include PFS, overall response rate, disease control rate, quality of life based on patient-reported outcomes, safety and tolerability, pharmacokinetics and biomarkers.

About Evofosfamide Evofosfamide (previously known as TH-302) is an investigational hypoxia-activated prodrug of a bis-alkylating agent that is preferentially activated under severe hypoxic tumor conditions, a feature of many solid tumors. Areas of low oxygen levels (hypoxia) in solid tumors are due to insufficient blood vessel supply. Similarly, the bone marrow of patients with hematological malignancies has also been shown, in some cases, to be severely hypoxic.

Evofosfamide is being studied in patients with locally advanced unresectable or metastatic soft tissue sarcoma and in patients with locally advanced unresectable or metastatic pancreatic cancer. Evofosfamide is also being investigated in a Phase 2 study designed to support registration for the treatment of non-squamous non-small cell lung cancer, and in earlier-stage clinical studies of other solid tumors and hematological malignancies.

Threshold has a global license and co-development agreement for evofosfamide with Merck KGaA, Darmstadt, Germany.

About Threshold Pharmaceuticals Threshold Pharmaceuticals, Inc. is a biotechnology company focused on the discovery and development of drugs targeting tumor hypoxia, the low oxygen condition found in the microenvironments of most solid tumors as well as the bone marrows of some patients with hematologic malignancies. This approach offers broad potential to treat a variety of cancers. By selectively targeting tumor cells, we are building a pipeline of drugs that hold promise to be more effective and less toxic to healthy tissues than conventional anticancer drugs. For additional information, please visit our website ( www.thresholdpharm.com ).

Forward-Looking Statements Except for statements of historical fact, the statements in this press release are forward-looking statements, including statements regarding the therapeutic potential of Threshold's product candidates, including the potential for Threshold's evofosfamide Phase 2 clinical trial to support registration for the treatment of patients with non-squamous non-small cell lung cancer. These statements involve risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include, but are not limited to: the difficulty and uncertainty of pharmaceutical product development, including the time and expense required to conduct clinical trials and analyze data, and the uncertainty of clinical success and regulatory approval; risks related to Threshold's dependence upon its collaborative relationship with Merck KGaA, Darmstadt, Germany, to further develop evofosfamide; the risks that the development of evofosfamide could be abandoned altogether as a result of the negative efficacy results in the Phase 3 studies or otherwise, and that even if its development continues, evofosfamide may never receive any marketing approvals; and Threshold's need for and the availability of resources to develop its product candidates and to support Threshold's operations. Further information regarding these and other risks is included under the heading "Risk Factors" in Threshold's Quarterly Report on Form 10-Q, which has been filed with the Securities and Exchange Commission on November 2, 2015 and is available from the SEC's website ( www.sec.gov ) and on our website ( www.thresholdpharm.com ) under the heading "Investors." We undertake no duty to update any forward-looking statement made in this news release.

Contact Laura Hansen, Ph.D. Senior Director, Corporate Communications Phone: 650-474-8206 E-mail: lhansen@thresholdpharm.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Rosalind Franklin University’s $23.8M Scholarship Win

Updated Category News Views 47

Twenty-three million dollars can disappear fast in graduate health education, which is exactly why Rosalind Franklin University’s campaign result deserves more than a polite round of applause. The university’s five-year Empowering Scholars effort closed in June 2026 with $23,836,272 raised, clearing its $20 million target by roughly 19%. In a world where institutions...

Continue Reading
Danaher and Microsoft Put AI Into the Lab Stack Early

Updated Category News Views 103

Laboratory AI gets interesting only when it reaches the hardware bench, and Danaher is taking a serious swing at that ugly, complicated job with Microsoft. The Nov. 20 partnership is not just another chatbot bolted onto a dashboard. It is aimed at building a common agentic platform that can help instruments interpret scientific intent, guide setup, control hardware within...

Continue Reading
CCTV-4 Revisits China's Enduring Academy Tradition

Updated Category News Views 86

Stone courtyards, old books and hard questions are getting prime time on CCTV-4, which is a more interesting programming bet than it may first appear. Enduring Chinese Academies, a ten-episode cultural exploration series from China Media Group's Global Chinese Programming Center, is built around a simple theme: “One academy, one spirit.” It begins airing November 22...

Continue Reading
Neurelis Founder Earns EY's 2026 Top Entrepreneur Honor

Updated Category News Views 65

Some business awards are wallpaper; this one carries real clinical weight. EY US named Craig Chambliss, CEO and co-founder of Neurelis, its Entrepreneur Of The Year 2026 National Overall Award winner. In a sector where plenty of companies talk grandly about changing lives and then vanish into the regulatory fog, the underlying story matters more than the trophy. Neurelis...

Continue Reading
Oatly’s $4.13 Tender Offer Is a Legal Detour, Not a Sale

Updated Category News Views 39

A $4.13 cash offer trading against a $7.17 close is the sort of thing that makes investors squint hard, and Verlinvest is practically waving a flag telling them why. This is not a conventional attempt to buy Oatly Group AB. It is a technical tender offer built to satisfy Swedish takeover rules while Verlinvest buys out its joint-venture partner’s interest in Oatly’s...

Continue Reading
Surgery Partners Deal Faces Fresh Price Scrutiny Ahead

Updated Category News Views 66

A $23.50 cash offer can look wonderfully tidy until somebody asks how the number was built. That is where Surgery Partners shareholders find themselves after Halper Sadeh LLC said it is investigating the proposed sale of Surgery Partners, Inc. to HealthSpan Partners. The firm is examining whether the company’s board obtained a fair price, ran a conflict-free process,...

Continue Reading
CITGO Sign Return Caps Kenmore's Careful Rebuild Work

Updated Category News Views 62

Thirty feet upward and 120 feet eastward is not the sort of move that usually stops a city in its tracks, yet Boston’s CITGO Sign was never merely rooftop hardware. Its public relighting in Kenmore Square marks the final phase of the redevelopment at 660 Beacon Street, and the real accomplishment is less flashy than the lights: a beloved, federally landmarked object...

Continue Reading
Sports Leagues Confront Youth Gambling's Hard Truth

Updated Category News Views 35

A stadium-sized advertising machine cannot pretend kids are not watching. That is the uncomfortable backdrop to the National Council on Problem Gambling's November 10 youth gambling prevention summit, where representatives from the NFL, MLB, NBA and PGA Tour met at the NFL's New York offices. Good that they showed up. Frankly, with gambling stitched into so much sports...

Continue Reading
University of Phoenix Poll Gets a Useful Reality Check

Updated Category News Views 0

Good Numbers, With the Usual Fine Print Employer approval is the kind of evidence career-focused schools desperately need, and University of Phoenix just put up a pretty loud batch of it. Among managers who directly supervise its graduates, 94% said the university understands employer needs, while 92% said its programs align with workforce demands. Those are stout...

Continue Reading
PexarBolt's CES Honor Meets a Real Crowdfunding Test

Updated Category News Views 32

A little touchscreen bolted onto a dock would usually make me roll my eyes. This time, Pexar has at least put enough muscle behind the gimmick to deserve a harder look. The PexarBolt Ultra TBT5 Dock was named a CES Innovation Awards 2027 Honoree in Computer Peripherals & Accessories, following an IFA 2026 Innovation Awards honor only two months after its launch. Awards do...

Continue Reading

Top 5 Most Recently Viewed Articles

Navigating the Shifting Landscape of European Credit Markets

Updated Category News Views 140

Understanding European Credit Markets In recent discussions, many have highlighted the significant progress in European equities, which have surged to unprecedented highs due to several bullish factors. These include attractive valuations, supportive monetary policies, evolving geopolitical conditions, and vital reforms. Similar Trends in Credit Markets However, it's...

Continue Reading
Exploring the Daily Fund Prices of WisdomTree ETFs

Updated Category News Views 153

Understanding Net Asset Values in WisdomTree ETFs When you dive into investments, net asset value (NAV) becomes a crucial concept, particularly within exchange-traded funds (ETFs). WisdomTree, recognized for its wide variety of ETFs, shares daily updates on its fund prices. This information is vital for investors who want to make informed choices. These daily fund prices...

Continue Reading
Ryan Mueller of MLG Capital Honored as Multifamily Influencer

Updated Category News Views 270

Ryan Mueller Recognized as a Multifamily Influencer MLG Capital, a prominent name in private real estate investments, has announced that Ryan Mueller, the Principal and Senior Vice President, has earned recognition as a 2025 Influencer in Multifamily Real Estate by GlobeSt. This prestigious accolade highlights Ryan's exceptional contributions and leadership in the sphere...

Continue Reading
Ames Watson Steps In to Lead Champion Brand's New Era

Updated Category News Views 491

Ames Watson Takes Charge of Champion's Collegiate and Teamwear Divisions Ames Watson is set to drive significant growth and innovation for the renowned sportswear brand Champion. Following a recent acquisition by Authentic Brands Group, Ames Watson will steer Champion's storied collegiate apparel and teamwear operations. This partnership marks a strategic step in...

Continue Reading
TFA Logistics Expands Operations with Dillon Transportation Deal

Updated Category News Views 586

TFA Logistics Expands Operations with Dillon Transportation Deal TFA Logistics, a prominent freight and logistics solutions provider, has successfully completed the acquisition of the assets belonging to Dillon Transportation. This strategic move significantly enhances TFA's national operations and adds over 130 talented employees to its team. Strengthening the National...

Continue Reading